TY - JOUR
T1 - Shortest Distance From Fovea to Subfoveal Hemorrhage Border Is Important in Patients With Neovascular Age-related Macular Degeneration
AU - Kherani, Saleema
AU - Scott, Adrienne W.
AU - Wenick, Adam S.
AU - Zimmer-Galler, Ingrid
AU - Brady, Christopher J.
AU - Sodhi, Akrit
AU - Meyerle, Catherine
AU - Solomon, Sharon D.
AU - Shaukat, Rimsha
AU - Channa, Roomasa
AU - Adeyemo, Olukemi
AU - Handa, James T.
AU - Wang, Jiangxia
AU - Campochiaro, Peter A.
N1 - Funding Information:
Funding/Support: Supported by Biostatistics Core Grant EY01765 to the Wilmer Eye Institute. Financial Disclosures: Adrienne W. Scott is a paid advisor for Allergan. Peter A. Campochiaro is a paid advisor for Aerpio Therapeutics, Alimera, Allergan, Applied Genetic Technologies, AsclipiX, Genentech/Roche, Graybug, Rxi, Merck, Allegro, Intrexon, Novartis, Astellas, and Exonate. JHU receives grants on his behalf from Alimera, Allergan, Aerpio Therapeutics, Genentech/Roche, Genzyme, AsclipiX, Oxford Biomedica, Regeneron, Regenxbio, and Clearside. He has equity in Graybug and Allegro. The following authors have no disclosures: Saleema Kherani, Adam S. Wenick, Ingrid Zimmer-Galler, Christopher J. Brady, Akrit Sodhi, Catherine Meyerle, Sharon D. Solomon, Rimsha Shaukat, Roomasa Channa, Olukemi Adeyemo, James T. Handa, and Jiangxia Wang. The authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/5
Y1 - 2018/5
N2 - Purpose: To identify factors influencing visual outcome in patients with neovascular age-related macular degeneration (NVAMD) and subfoveal hemorrhage (SFH) treated with anti–vascular endothelial growth factor (VEGF) agents. Design: Retrospective case series. Methods: Anti-VEGF-treated eyes with SFH > 1 disc area (DA) were identified (n = 16) and changes in visual acuity (VA) and central subfield thickness (CST) from baseline to last follow-up, along with SFH area, thickness, minimum distance from fovea to SFH border, and time to resolution, were determined. Results: At baseline, mean (± standard error of the mean) size and thickness of SFH were 14.9 ± 2.8 DA and 386.6 ± 46.9 μm, and mean Snellen VA and CST were 20/250 and 591.7 ± 57.0 μm. Median follow-up was 47.6 months. While more than 50% of patients had VA ≤ 20/200 at baseline and all time points through week 48, the percentage of patients with VA ≥ 20/50 increased to 30%–40% at months 6 and 12 and remained stable through month 48. Spearman rank correlation demonstrated 2 independent variables that correlated with good visual outcome, smaller area of SFH at baseline (r = −0.630; P =.009), and high frequency of anti-VEGF injections (r = 0.646; P =.007). In exceptional patients with good visual outcome despite large baseline SFH, shortest distance between the fovea and hemorrhage border significantly correlated with baseline VA (r = −0.503, P =.047) and final VA (r = −0.575, P =.02). Conclusions: Patients with NVAMD and thick SFH, but short distance between fovea and uninvolved retina, can have good visual outcomes when given frequent anti-VEGF injections.
AB - Purpose: To identify factors influencing visual outcome in patients with neovascular age-related macular degeneration (NVAMD) and subfoveal hemorrhage (SFH) treated with anti–vascular endothelial growth factor (VEGF) agents. Design: Retrospective case series. Methods: Anti-VEGF-treated eyes with SFH > 1 disc area (DA) were identified (n = 16) and changes in visual acuity (VA) and central subfield thickness (CST) from baseline to last follow-up, along with SFH area, thickness, minimum distance from fovea to SFH border, and time to resolution, were determined. Results: At baseline, mean (± standard error of the mean) size and thickness of SFH were 14.9 ± 2.8 DA and 386.6 ± 46.9 μm, and mean Snellen VA and CST were 20/250 and 591.7 ± 57.0 μm. Median follow-up was 47.6 months. While more than 50% of patients had VA ≤ 20/200 at baseline and all time points through week 48, the percentage of patients with VA ≥ 20/50 increased to 30%–40% at months 6 and 12 and remained stable through month 48. Spearman rank correlation demonstrated 2 independent variables that correlated with good visual outcome, smaller area of SFH at baseline (r = −0.630; P =.009), and high frequency of anti-VEGF injections (r = 0.646; P =.007). In exceptional patients with good visual outcome despite large baseline SFH, shortest distance between the fovea and hemorrhage border significantly correlated with baseline VA (r = −0.503, P =.047) and final VA (r = −0.575, P =.02). Conclusions: Patients with NVAMD and thick SFH, but short distance between fovea and uninvolved retina, can have good visual outcomes when given frequent anti-VEGF injections.
UR - http://www.scopus.com/inward/record.url?scp=85043602120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043602120&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2018.02.015
DO - 10.1016/j.ajo.2018.02.015
M3 - Article
C2 - 29499174
AN - SCOPUS:85043602120
SN - 0002-9394
VL - 189
SP - 86
EP - 95
JO - American journal of ophthalmology
JF - American journal of ophthalmology
ER -